Pilot Study of Reduced Venetoclax Exposure
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
- Status
- RECRUITING
- Phase
- PHASE3
MRD-positive AML Clinical Study
- Status
- RECRUITING
- Phase
- NA
A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
- Status
- RECRUITING
- Phase
- PHASE2
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
- Status
- RECRUITING
- Phase
- PHASE4
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
- Status
- RECRUITING
- Phase
- PHASE2
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease
- Status
- RECRUITING
- Phase
- PHASE2
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
- Status
- RECRUITING
- Phase
- PHASE2
Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
- Status
- RECRUITING
- Phase
- PHASE2
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Status
- RECRUITING
- Phase
- PHASE3
Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2